Pular para o conteúdo principal
Ranking Invest

RAPT - RAPT Therapeutics, Inc.

Segmento: HealthcareRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
-$ 182.90 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 177.37 Mi

Dívida Líquida

-$ 56.42 Mi

L4T

-$ 116.51 Mi

Indicadores Básicos

ROE

-65.69%

Índices de Previsibilidade

Faturamento

G0.71

Lucro

B0.15

Margem

D0.78

Índices de Tendência

Faturamento

F-10.61

Lucro

F-5.88

Margem

A8.55

Índices de Endividamento

DIV/PAT

-0.32

DIV/L4T

0.48

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.